ENTA Enanta Pharmaceuticals Inc
Price (delayed)
$5.67
Market cap
$120.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.95
Enterprise value
$93.46M
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections
Highlights
The EPS has grown by 25% year-on-year and by 10% since the previous quarter
ENTA's net income is up by 24% year-on-year and by 10% since the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 3.4% QoQ
The debt has soared by 125% YoY and by 3.6% from the previous quarter
The equity has decreased by 42% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of ENTA
Market
Valuations
Earnings
Shares outstanding
21.33M
Market cap
$120.96M
Enterprise value
$93.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
1.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.4
Revenue
$66.59M
Gross profit
$66.59M
Operating income
-$110.35M
Net income
-$104.93M
EBIT
-$97M
EBITDA
-$94.42M
Free cash flow
-$96.48M
Per share
Balance sheet
Liquidity
EPS
-$4.95
EPS diluted
-$4.95
Free cash flow per share
-$4.54
Book value per share
$5.28
Revenue per share
$3.14
TBVPS
$16.42
Total assets
$348.64M
Total liabilities
$236.83M
Debt
$57.46M
Equity
$111.82M
Working capital
$219.1M
Debt to equity
0.51
Current ratio
5.47
Quick ratio
4.59
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
-141.8%
Gross margin
100%
Net margin
-157.6%
Operating margin
-165.7%
Return on assets
-27.3%
Return on equity
-75.5%
Return on invested capital
-29.8%
Return on capital employed
-32.4%
Return on sales
-145.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTA stock price
How has the Enanta Pharmaceuticals stock price performed over time
Intraday
1.25%
1 week
11.18%
1 month
-8.55%
1 year
-56.11%
YTD
-1.39%
QTD
2.72%
Financial performance
How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$66.59M
Gross profit
$66.59M
Operating income
-$110.35M
Net income
-$104.93M
Gross margin
100%
Net margin
-157.6%
ENTA's net income is up by 24% year-on-year and by 10% since the previous quarter
The company's operating income rose by 22% YoY and by 9% QoQ
The net margin has grown by 16% YoY and by 8% from the previous quarter
The operating margin has grown by 14% YoY and by 8% from the previous quarter
Growth
What is Enanta Pharmaceuticals's growth rate over time
Valuation
What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.07
P/S
1.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.4
The EPS has grown by 25% year-on-year and by 10% since the previous quarter
ENTA's P/B is 55% below its 5-year quarterly average of 2.4 and 37% below its last 4 quarters average of 1.7
The equity has decreased by 42% YoY and by 13% from the previous quarter
The price to sales (P/S) is 78% lower than the 5-year quarterly average of 8.3 and 48% lower than the last 4 quarters average of 3.5
Enanta Pharmaceuticals's revenue has decreased by 10% YoY
Efficiency
How efficient is Enanta Pharmaceuticals business performance
Enanta Pharmaceuticals's return on equity has decreased by 25% YoY and by 3.4% QoQ
ENTA's return on invested capital is up by 25% year-on-year and by 3.9% since the previous quarter
The return on sales has grown by 16% year-on-year and by 8% since the previous quarter
Enanta Pharmaceuticals's ROA has increased by 15% YoY and by 4.9% from the previous quarter
Dividends
What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTA.
Financial health
How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 47% higher than its total liabilities
The company's total assets fell by 19% YoY and by 7% QoQ
Enanta Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 3.4% QoQ
The debt is 49% less than the equity
The debt has soared by 125% YoY and by 3.6% from the previous quarter
The equity has decreased by 42% YoY and by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.